Welcome to our dedicated page for PRF Technologies news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on PRF Technologies stock.
PRF Technologies Ltd. reports developments across clinical-stage specialty pharmaceuticals and AI-driven solar analytics. The company focuses on reformulating established therapeutics for post-operative pain management and, through majority-owned LayerBio, is developing OcuRing™-K, a bio-erodible intraocular ring designed to deliver ketorolac for post-cataract pain and inflammation.
PRF news also covers the company’s DeepSolar business unit, which develops AI-driven digital asset management, forecasting, performance monitoring, and technical due diligence tools for utility-scale solar plants. Recurring updates include ocular drug-delivery regulatory milestones, preclinical and clinical safety data, patent activity, SaaS deployments, commercial collaborations, capital actions, and governance changes.
PRF Technologies (PRFX) plans to establish GridFeed™, together with its DeepSolar operations, as a standalone, wholly owned subsidiary to focus on the growth and commercialization of its AI-driven renewable energy trading technology.
The new structure is intended to let GridFeed pursue strategic investments, partnerships and commercial collaborations directly with renewable producers, traders, utilities, technology firms and sector-focused investors. GridFeed’s platform uses DeepSolar’s AI engine, combining localized weather intelligence, production forecasting, battery storage orchestration and market analytics to support day-ahead, intraday and continuous trading decisions. The company reports validation of the AI engine with real-world European data, acceptance into the NVIDIA Connect program and filing of a patent application for plant-level microclimate forecasting. GridFeed will be showcased at Energy Trading Week Europe 2026 in London, while PRF continues healthcare programs and ended Q2 2026 with about $11.6 million in cash.
PRF Technologies (PRFX) reported first half 2026 results and a broad business update across its healthcare and AI energy segments.
In ophthalmology, the FDA cleared the IND for OcuRing™-K, enabling a U.S. multi-center Phase II cataract-surgery trial, with enrollment expected in the second half of 2026. In post-operative pain, PRF-110 showed sustained 72-hour analgesic activity comparable to ZYNRELEF® in a porcine model using a ropivacaine-only, NSAID-free formulation, with expanded data indicating slower systemic absorption and enhanced local tissue retention.
In energy, the DeepSolar platform added commercial collaborations, validated its Predict™ optimization engine on real-world European data, expanded into battery storage and unveiled the GridFeed™ trading platform, and began generating revenue from SaaS and service engagements. As of June 30, 2026, cash and equivalents were approximately $11.6 million, supported by a $10.0 million equity raise, while R&D spending increased and G&A expenses declined 39% year-over-year.
PRF Technologies (Nasdaq: PRFX) reported in a shareholder letter that it raised $10 million on May 28, 2026 through its equity line facility, which the company says substantially strengthened its balance sheet and increased strategic flexibility for growth initiatives.
The biotechnology subsidiary LayerBio is completing operational and clinical preparations for a planned Phase 2 trial of OcuRing-K, an ocular implant used during cataract surgery, while lead candidate PRF-110 showed expanded preclinical data with sustained 72-hour analgesic activity versus an approved extended-release benchmark.
In renewable energy, DeepSolar validated its Predict platform with European market data, added Battery-to-Revenue Intelligence for storage assets, joined the NVIDIA Connect program and plans to showcase GridFeed at Energy Trading Week Europe 2026.
PRF Technologies (Nasdaq: PRFX) announced that its DeepSolar business unit will participate in Energy Trading Week Europe 2026, held September 24–25, 2026 at the Business Design Centre in London. The event is expected to attract over 2,500 energy trading professionals.
PRF plans to showcase GridFeed™, its AI-driven platform for renewable energy trading, market participation and revenue optimization, built on the DeepSolar Predict AI engine. The company expects to present to traders, asset owners, operators and balancing responsible parties, join an industry panel and hold meetings with prospective customers and partners as part of its go-to-market strategy.
PRF Technologies (Nasdaq: PRFX) announced an expansion of its AI-driven renewable energy revenue optimization platform, DeepSolar Predict, adding a Battery-to-Revenue Intelligence capability that extends optimization workflows from solar assets to battery energy storage.
The new feature is designed to link storage availability, operating constraints and market conditions into decision-support workflows, supporting decisions on when to store, dispatch or preserve battery capacity. It follows recently completed real-world validation of DeepSolar Predict using European market data, as PRF advances the solution toward planned commercial launch and integrates it into its future GridFeed trading platform.
PRF Technologies (Nasdaq: PRFX) announced that its DeepSolar unit has completed initial validation of DeepSolar Predict, an AI-based revenue optimization platform for renewable energy markets.
The validation used real-world European-style utility-scale production, weather and market data across day-ahead and intraday scenarios as the platform progresses toward planned commercial launch.
PRF Technologies (Nasdaq: PRFX) reported expanded preclinical results for its lead candidate PRF-110 in a head-to-head study against approved benchmark ZYNRELEF in a validated porcine post-operative pain model.
Data showed comparable analgesic efficacy, slower absorption, enhanced local tissue retention and sustained exposure, supporting development as a single-administration, long-acting post-surgical analgesic aimed at reducing opioid use.
PRF Technologies (Nasdaq: PRFX) is advancing its AI platform DeepSolar Predict toward planned commercial launch. The solution targets revenue optimization for solar, wind and battery storage by combining weather intelligence, AI forecasting, storage optimization and real-time market decision support.
The platform builds on DeepSolar’s NVIDIA Connect participation and a patent application for plant-level micro-climate modeling intended to improve solar production forecasts. Planned capabilities include localized weather modeling, production and portfolio forecasting, imbalance risk tools, battery storage orchestration and market-informed delivery planning across renewable asset portfolios.
PRF Technologies (Nasdaq:PRFX) reported positive preclinical data for its lead post-operative pain candidate PRF-110 in a head-to-head pig study versus approved benchmark ZYNRELEF. PRF-110 showed sustained, 72-hour analgesic activity comparable to ZYNRELEF using a ropivacaine-only, NSAID-free extended-release formulation.
According to PRF, both products reduced pain-related measures, PRF-110 maintained comparable efficacy at later timepoints, and safety and local tolerability were consistent with prior preclinical experience, with no unexpected findings. The company believes these results will support future development and regulatory strategy for PRF-110.
PRF Technologies (Nasdaq: PRFX) announced FDA clearance of its IND for OcuRing-K, a bio-erodible intraocular ring to deliver ketorolac as a single intraoperative application.
The clearance enables a U.S. multi-center Phase II trial with enrollment expected in the second half of 2026, evaluating pain, inflammation, and safety after cataract surgery.